Journal article icon

Journal article

A first-in-man phase i and pharmacokinetic study on CHR-2797 (Tosedostat), an inhibitor of M1 aminopeptidases, in patients with advanced solid tumors.

Abstract:

PURPOSE: To determine the maximum tolerated dose, dose-limiting toxicity, pharmacokinetics, and preliminary therapeutic activity profile of CHR-2797 (tosedostat), a novel, orally bioavailable inhibitor of the M1 family of aminopeptidases with antiproliferative and antiangiogenic activity in vitro. EXPERIMENTAL DESIGN: A phase I study of accelerated titration design that escalated through nine doses (10-320 mg) in patients (Eastern Cooperative Oncology Group performance status, < or =2) wit...

Expand abstract
Publication status:
Published

Actions


Access Document


Authors


Protheroe, A More by this author
Hayward, N More by this author
Expand authors...
Journal:
Clinical cancer research : an official journal of the American Association for Cancer Research
Volume:
15
Issue:
15
Pages:
4978-4985
Publication date:
2009-08-05
DOI:
EISSN:
1557-3265
ISSN:
1078-0432
URN:
uuid:5bbf3551-0b98-403c-b7a6-428f53ba489e
Source identifiers:
125091
Local pid:
pubs:125091

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP